Ecosystem
From bench research to global scale, one governed sequence.
AXIOM is not a directory of projects. It is an operating model where each asset advances only after passing an explicit scientific, legal and financial gate.
Value chain
The nine gates.
- 01
Research
Origination from universities, ICTs and corporate labs, screened against market pull.
- 02
Prototype
Proof-of-concept engineering with defined success criteria and a costed development plan.
- 03
Scientific validation
Independent replication, GLP studies and peer-reviewed publication of core claims.
- 04
IP protection
Freedom-to-operate analysis, priority filings and PCT strategy per target market.
- 05
Valuation
Risk-adjusted NPV and comparables, audited assumptions, sensitivity ranges disclosed.
- 06
Capital raising
Structured rounds with VC, family offices, ESG funds and Lei do Bem corporate sponsorship.
- 07
Licensing
Territory and field-of-use agreements with milestone architecture and audit rights.
- 08
Royalties
Transparent royalty accounting, quarterly reporting and secondary participation options.
- 09
Global scale
International partners, regulatory expansion and manufacturing transfer at scale.
Who operates in the ecosystem
Six mandates, one infrastructure.
Corporates (Lucro Real)
Sponsor eligible R&D under Lei do Bem, secure early access to technology and reduce innovation risk.
Pharma, food & healthtech
License validated assets by territory and field of use, with technology transfer support.
Investors & family offices
Access risk-adjusted valuations, staged capital structures and royalty-backed participation.
ESG & impact funds
Deploy capital against measured environmental, social and scientific outcomes mapped to UN SDGs.
Universities & ICTs
Convert research output into protected, valued and licensable assets without losing academic autonomy.
Government & international partners
Coordinate national innovation priorities with private capital and cross-border technology transfer.